Login to Your Account



Clinic Roundup


Wednesday, March 14, 2012
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it achieved strong T-cell immune responses in a Phase I study of Pennvax-B, its product for treating the HIV subtype prevalent in North America and Europe. All 12 HIV-positive patients completed the four-dose vaccination regimen, and there were no adverse events or vaccine-related Grade 3 or Grade 4 adverse events noted. The interim results were presented at the Vaccine World Summit 2012 meeting in Hyderabad, India.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription